/

BPTH

Bio-Path Holdings, Inc.Closed

0.000300+0.00 +50.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.000100

Prev close

0.000200

Day range

0.0001000.000100

52-week range

0.0001000.1134

Volume

1040.00×

Mkt cap

15.09K

P/E ttm

—

Fwd P/E

-0.00

EPS ttm

-1.14

Div yield

0.00%

Earnings

—

From 52w high

−99.74%

Price Chart

Yahoo Finance · delayed

BPTHOct 12, 2026O 0.0003H 0.0003L 0.0003C 0.0003+0.0001 (+50.00%)Vol 3.00K

SMA 500.0218
SMA 2000.0513

1Y change −99.55% since Oct 10, 2025 close504 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BPTH Bio-Path Holdings, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −40.00%
1 month: +200.00%
3 months: −99.14%
6 months: −99.52%
Year to date: −99.50%
1 year: −99.55%

Valuation & ownership

Market cap: 15.09K
Enterprise value: 534.09K
P/E (ttm): —
Forward P/E: -0.00
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: -0.31
EPS (ttm): -1.14
EPS (forward): -4.04
Beta (5y monthly): -0.43
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 50.30M
Float: 50.30M
Short % of float: 8.03%
Short ratio (days): 0.92
Held by insiders: 0.00%
Held by institutions: 0.87%
Avg volume (3m): 35.21K
50-day average: 0.0172
200-day average: 0.0428
52-week change: −99.55%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 31.0
vs 50-day SMA: −98.63%
vs 200-day SMA: −99.42%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 1485.26%
Realised vol (20d, ann.): 1030.1%
From 52-week high: −99.74%
From 52-week low: +200.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Bio-Path Holdings, Inc.

Yahoo Finance profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Sector: Healthcare
Industry: Biotechnology
Employees: 1
Headquarters: Bellaire, TX, United States
Website: biopathholdings.com
Officers: Dr. Douglas P. Morris Co-Founder, Director of Investor Relations & Secretary
Mr. Vikram Paul Grover C.F.A., Esq.

SEAS

Seasonality · BPTH

2008–2026 · monthly returns

Strongest month Mar +36.87%Weakest month Jul −10.58%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.3	1.7	1.7	-7.8	-42.1	46.9	-19.1	-31.6	-99.6	200.0			−99.5%
2025	-30.4	-77.7	-5.5	-20.5	25.8	0.0	-11.8	-27.9	-46.7	71.1	-24.9	-18.9	−94.8%
2024	-11.2	-26.0	-32.2	-31.3	-27.2	-2.9	-21.0	-37.6	-7.8	-0.5	-15.0	50.6	−87.5%
2023	37.7	-13.0	-23.2	1.4	17.0	7.9	-40.4	-61.1	-10.4	78.2	-15.4	-17.0	−69.3%
2022	-9.8	10.3	2.4	-23.7	21.8	8.4	-8.0	2.8	-12.8	1.9	-54.8	2.7	−59.9%
2021	18.3	56.5	8.3	-15.1	-4.4	17.0	-4.0	-11.3	-9.7	-7.6	-6.5	-14.9	+7.7%
2020	-20.8	-13.4	-17.9	14.7	7.2	-8.7	0.4	-15.2	-1.4	-22.6	7.9	-1.1	−56.2%
2019	-39.5	22.9	684.2	-14.0	-27.4	5.2	2.0	-18.7	-14.5	13.8	-32.9	10.2	+128.3%
2018	2.2	-18.3	18.3	-14.0	-6.4	-7.5	-10.1	1.5	-56.6	-32.2	10.7	-60.5	−91.4%
2017	-29.6	-13.9	1.1	-23.7	-44.5	10.9	-6.7	-24.0	30.9	9.7	-30.1	-26.7	−85.0%
2016	12.0	27.1	45.5	-10.8	17.3	-26.6	-14.6	-10.0	-8.5	-28.6	23.0	9.8	+8.0%
2015	-15.0	-18.1	-2.7	-13.6	-22.8	-4.2	11.3	-14.1	3.6	36.8	1.3	-20.9	−53.0%
2014	10.3	-5.0	-36.8	-10.2	10.5	16.0	-25.2	1.3	-13.0	45.3	-15.8	8.1	−33.5%
2013	-8.6	9.4	34.3	14.9	-5.6	0.0	-5.9	20.6	176.3	43.1	7.0	63.3	+1042.9%
2012	-29.7	38.2	-8.8	-6.5	24.1	3.4	0.7	4.0	-5.1	-10.8	-15.2	25.0	+0.0%
2011	16.5	22.0	-15.3	-3.1	-7.3	-18.2	-3.5	16.7	0.0	-8.6	-3.1	12.9	−0.6%
2010	-18.6	2.9	27.8	-4.3	4.5	-13.0	7.5	-2.3	-4.8	-2.5	-7.7	-2.2	−18.1%
2009	18.2	-44.6	-52.8	29.4	40.9	-19.4	-36.0	-6.3	120.0	6.1	28.6	-4.4	−21.8%
2008				12.2	296.0	-40.0	-25.0	-5.6	-17.6	-14.3	-33.3	-31.3	−38.9%

BPTH

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BPTH

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Bio-Path Holdings, Inc.

Seasonality · BPTH

Insider Activity · BPTH

Congress Trades · BPTH

Investors Holding BPTH

Investors Holding BPTH

Congress Trades · BPTH

Insider Activity · BPTH

Seasonality · BPTH

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Bio-Path Holdings, Inc.

Earnings & Dividends

News